Neonatal invasive candidiasis: A prospective multicenter study of 118 cases

Neonatal invasive candidiasis: A prospective multicenter study of 118 cases
复制标题

DOI:
10.1055/s-2003-40008
复制
发表时间:
2003-04-01
影响因子:
2
通讯作者:
Colomer, BF
Colomer, BF
中科院分区:
医学4区
文献类型:
--
作者:
Sastre, JBL;Cotallo, GDC;Colomer, BF

文献摘要

被引文献

相似文献

进行了一项前瞻性多中心研究,以评估西班牙新生儿侵袭性念珠菌病的流行病学。在18个月期间,27个参与新生儿单位共收治20,565名新生儿,其中118名(0.57%)新生儿被诊断为系统性念珠菌病。从79名婴儿的血液中分离出念珠菌,从33名婴儿的尿液中分离出念珠菌,从4名婴儿的脑脊液中分离出念珠菌;在2例病例中,尸检时发现深部组织念珠菌病的组织学证据。极低出生体重儿(≤ 1500 g)全身念珠菌病的发病率(4.8%)明显高于体重> 1500 g的婴儿(0.2%)(P < 0.001)。白色念珠菌是最常见的菌种(52.5%),其次是近平滑念珠菌(23.7%)和热带念珠菌(7.6%)。只有7名婴儿接受了阿替霉素B(初始剂量0.18 +/- 0.3 mg/kg,最大日剂量1.7 +/- 0.9 mg/kg)治疗,但其中3名婴儿(43%)因肾毒性而停止治疗。81例新生儿给予脂质体阿替霉素B,29例给予阿替霉素B脂质复合物。在死亡率和不良反应发生率方面,与脂质体阿替霉素B或阿替霉素B脂质复合物治疗没有差异。死亡率为10.2%,所有死亡均发生在伴念珠菌血症的VLBW队列中。
A prospective multicenter study was conducted to assess the epidemiology of neonatal invasive candidiasis in Spain. In a total of 20,565 admissions to the 27 participating neonatal units over an 18-month period, systemic candidiasis was diagnosed in 118 (0.57%) neonates. Candida species were isolated from the blood in 79 infants, from the urine in 33, and from the cerebrospinal fluid in 4; in 2 cases, histologic evidence of deep tissue candidiasis was found at autopsy. Very-low-birth-weight (VLBW) infants (less than or equal to 1500 g) showed a significantly higher incidence of systemic candidiasis (4.8%) than infants weighing > 1500 g (0.2%) (P < 0.001). Candida albicans was the most frequent species (52.5%) followed by C parapsilosis (23.7%), and C tropicalis (7.6%). Only seven infants were treated with amphotericin B (initial dose 0.18 +/- 0.3 mg/kg, maximal daily dose 1.7 +/- 0.9 mg/kg) but treatment was stopped in three of them (43%) due to nephrotoxicity. Liposomal amphotericin B was given to 81 neonates and amphotericin B lipid complex to 29. There were no differences in mortality rate and in the incidence of adverse effects in relation to treatment with liposomal amphotericin B or amphotericin B lipid complex. The mortality rate was 10.2% and all deaths occurred in the VLBW cohort with candidemia.